Armata Pharmaceuticals, Inc.
AP-SA02
complicated bacteremia caused by Staphylococcus aureus
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews AP-SA02 for complicated bacteremia caused by Staphylococcus aureus around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“Announced that the FDA granted Fast Track Designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA, advancing AP-SA02 on a faster path to potential approval and patient access.”